TRIPLEROSE LIMITED

Financial Health Assessment: Triplerose Limited

1. Financial Health Score: B+

Explanation: Triplerose Limited is a mature, asset-rich patient with a strong immune system (cash reserves) and steady nutritional intake (profitability). However, the business suffers from inherently high "cholesterol" in the form of significant long-term debt, which is typical for its industry (real estate) but still poses a long-term risk requiring careful management. The patient is healthy and stable but must monitor its debt levels to avoid future complications.

2. Key Vital Signs

• Blood Pressure (Liquidity): Strong. The company’s current ratio stands at roughly 1.91:1 (£30.99m current assets / £16.21m current liabilities). This indicates healthy circulation, meaning the business can comfortably meet its short-term financial obligations without breaking a sweat.
• Pulse (Cash Position): Steady. Cash at bank is £6.72m, down slightly from £7.56m in 2023 but a massive improvement from the £65k reported in 2022. The pulse is strong, providing an excellent buffer against unexpected shocks.
• Cholesterol Levels (Gearing/Leverage): Elevated. Total liabilities sit at approximately £83.3m against equity of £77m. Long-term bank loans account for over £54m, supplemented by a £13.4m provision. While high, this is a common symptom for a property investment firm relying on mortgage financing. It requires ongoing monitoring, especially in fluctuating interest rate environments.
• Muscle Mass (Asset Base): Robust. Total assets have grown to £160.3m, with the vast majority (£128.2m) tied up in tangible land and buildings. The "muscle" is well-developed and forms the core strength of the business.
• Nutrition (Profitability): Healthy. The Profit and Loss reserve grew by £907k (£18.55m up from £17.64m), demonstrating that the business is consuming more calories than it burns. The asset base also grew year-on-year, indicating healthy organic growth.

3. Diagnosis

Condition: Robust Property Investor with Benign Leverage and Minor Receivables Shift

The underlying business health of Triplerose Limited is fundamentally sound. The company operates as a real estate investment vehicle, and its vitals reflect this specialized constitution. The significant recovery in cash reserves from 2022 to 2024 shows a business that has successfully managed its working capital cycle, perhaps through refinancing or improved rent collection.

However, the symptoms analysis reveals two areas requiring clinical observation: 1. Receivables Shift: Trade debtors dropped significantly from £5.27m to £1.07m, while "Other debtors" swelled from £17m to £23.2m. This shift suggests a change in the nature of what is owed to the company—possibly inter-company balances or accrued income. While currently benign, "other debtors" can sometimes mask underlying issues if they represent uncollectable or related-party balances that lack a defined repayment schedule. 2. Historical Equity Dip: Between 2022 and 2023, net assets dropped from £78.9m to £76.1m, before recovering to £77m in 2024. This suggests a prior-year "health scare"—likely a downward revaluation of investment properties or a withdrawal of profits—which has since stabilized.

The reliance on long-term debt (£53.6m falling due after more than one year) is the primary chronic condition. While well-managed currently, it leaves the patient sensitive to interest rate "blood pressure spikes."

4. Recommendations

To maintain and improve financial wellness, the following preventative and proactive measures are recommended:

• Cardiovascular Exercise (Debt Management): With over £54m in long-term bank loans, the company is highly sensitive to interest rate movements. It is recommended to stress-test the portfolio against current high-rate environments. Where possible, explore fixing interest rates or making opportunistic overpayments to reduce the debt burden.
• Diagnostic Testing (Investigate "Other Debtors"): The £23.2m in "Other debtors" should be reviewed. Ensure these balances are recoverable, properly secured, and not simply accumulating because of deferred maintenance or intra-group funding that lacks a clear repayment schedule. Write off any "toxins" (bad debts) promptly.
• Maintain Cash Reserves (Immune Support): The current cash position of £6.7m is excellent for a company of this size. Do not allow this buffer to erode. Maintaining strong liquidity ensures the company can weather void periods in its property portfolio without defaulting on loan covenants.
• Monitor Provisions: The £13.4m provision for liabilities (consistent across 2023 and 2024) should be regularly reviewed to ensure it accurately reflects future obligations. Over-provisioning ties up capital unnecessarily, while under-provisioning can lead to future financial shocks.